Volume 6 Supplement 3

Fifth Annual Research Conference: Innovation from Cell to Society

Open Access

Association of parental FEF25-75% during a methacholine challenge and children's PC20 and diagnosis of asthma

  • D Houlbrook1, 2,
  • AB Becker2 and
  • CD Ramsey3, 4
Allergy, Asthma & Clinical Immunology20106(Suppl 3):P32

DOI: 10.1186/1710-1492-6-S3-P32

Published: 26 November 2010

Background

There is evidence that paternal and maternal lung function influence children's pulmonary function. To date, the most widely used pulmonary function test (PFT) to assess airway responsiveness is the PC20 (concentration of methacholine required to decrease FEV1 by 20%). However, other measures of parental lung function may be better predictors of airway responsiveness or asthma development in their children.

Methods

The study population included children born in 1995 in Manitoba, who were enrolled in a nested case-control birth cohort study (Study of Asthma Genes and the Environment (SAGE). Both index children and their parents underwent PFTs and methacholine challenges to determine their PC20. Parents often had a normal PC20 but a change in flow at mid-lung volumes (forced expiratory flow at 25-75% vital capacity) was noted. Therefore, we measured parental PC30 (concentration of methacholine required to decrease FEF 25-75% by 30%) and its association with their child's PC20 and physician diagnosed asthma. A positive PC30 was measured at a concentration of ≤ 8 mg/ml. Children were assessed at age 12-13 by a pediatric allergist for a diagnosis of asthma. Odds ratios (OR) were calculated to examine the relationship between parental PC30 and a child's PC20 and asthma. This relationship was further explored by gender.

Results

Overall 114 children and their parents were included in this analysis. Of the 114 children, 47 were females (21 asthma) and 67 were boys (23 asthma). No significant relationship was seen between children diagnosed with asthma and having a parent with a PC30 ≤ 8 (OR 1.07; 95% CI 0.49-2.37) or both parents PC30 >8.

112 children [45 females (23 with PC20 ≤ 8) and 67 males (46 with PC20 ≤ 8)] fit the criteria for having a PC20 and participating parents. In children with a PC20 ≤ 8 there was no relationship between having one parent with PC30 ≤ 8 (OR 1.18; 95% CI .54-2.63) or both parents having a PC30 >8.

When we examined gender specific relationships, there was no association between fathers PC30 and having a son diagnosed with asthma (OR 1.32; 95% CI 0.5-3.5) or daughters with a diagnosis of asthma (OR 1.07; 95% CI 0.33-3.48). Similarly, there was no significant association between the father's PC30 and their child's PC20 being ≤ 8 mg/ml.

In moms with a PC30 ≤ 8 mg/ml there was no association with sons that had a PC20 ≤ 8 mg/ml (OR 1.0; 95% CI 0.51-2.0); However moms with a PC30 ≤ 8 were significantly more likely to have a daughter with a PC20 ≤ 8 (OR 3.56; 95% CI 1.55-8.21). In addition, there was a significant relationship between mom's PC30 being ≤ 8 and a daughter having physician diagnosed asthma (OR2.34; 95% CI 1.04-5.44). The relationship was in the same direction between maternal PC30 and a son's diagnosis of asthma, however this was not significant (OR 2.0; 95% CI 0.99-4.05).

Conclusion

There was no relationship between children's asthma and PC20 and parental airway responsiveness measured as PC30. There was a statistically significant relationship between daughter's airway responsiveness and asthma and mothers' airway responsiveness as a PC30 FEF 25-75%.

Maternal mid-flow responsiveness may be helpful in identifying risk for the development of pediatric asthma. Mid lung flow changes in mothers may represent a maternal genetic influence on the development of asthma in children.

Authors’ Affiliations

(1)
Manitoba Institute of Child Health
(2)
Department of Pediatrics, University of Manitoba
(3)
Department of Medicine, University of Manitoba
(4)
Department of Community Health Sciences, University of Manitoba

Copyright

© Houlbrook et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement